Compare General Dynamics Corporation (GD) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Medpace Holdings Inc — how do they compare? General Dynamics Corporation trades at $331.53 (market cap $89.26B), while Medpace Holdings Inc trades at $611.3 (market cap $16.82B). The key difference: General Dynamics Corporation is far larger — about 5.3× Medpace Holdings Inc's market cap, and General Dynamics Corporation pays a 1.93% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Dynamics Corporation for 85 Days and Medpace Holdings Inc for 14 Days on average.
| GD | MEDP | |
|---|---|---|
Market Cap | $89.26B | $16.82B |
Volume | 1,496,273 | 223,093 |
Sector | Industrials | Health |
52-Week High | $395.97 | $630.19 |
52-Week Low | $312.53 | $393.42 |
Typical Hold Time | 85 Days | 14 Days |
Enterprise Value | $94.40B | $16.44B |
Dividend Yield | 1.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $326.63, down 1.42% amid bearish technical signals, though fundamentals remain solid with consistent earnings beats and strong defense contract visibility. The stock shows oversold RSI readings while maintaining healthy profitability metrics including 8.18% net margin and 17.8% ROE. Recent Pentagon spending focus and dividend stability support the investment case despite near-term price pressure.
GD presents a compelling value opportunity with 57% analyst buy ratings and $420.57 consensus target representing 29% upside. Defense budget tailwinds and submarine/vehicle demand provide growth catalysts, though technical weakness and defense sector volatility pose near-term risks. The company's consistent cash flow generation and dividend payments offer stability for long-term investors.
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
